Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden.

Conclusions: M1 disease at PC diagnosis was associated with worse survival after CRPC onset versus M0. Higher Gleason score at diagnosis was associated with higher mortality after CRPC onset in M0 patients at diagnosis. PMID: 32266854 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research

Related Links:

This study investigated the performance of 68Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Six hundred sixty (660) patients with biochemical recurrence referred for positron-emission-tomography/computed-tomography with 68Ga-prostate-specific-membrane-antigen-11 were evaluated retrospectively. Prostate-specific-antigen-stratified cohorts of pathological scan results were analyzed, and relationships between prostate-specific-antigen kinetics and PSMA-positive tumor lesions were...
Source: Health Physics - Category: Radiology Tags: Papers Source Type: research
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Our purpose was to evaluate the performance of 11C-choline PET/CT in detecting biochemically recurrent prostate cancer (PCa) in a large non-European cohort (in the context of emerging evidence for prostate-specific membrane antigen PET in this setting) and to map patterns of PCa recurrence. Methods: We retrospectively analyzed 11C-choline PET/CT scans from 287 patients who were enrolled in an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean, 3.43 ng/mL; median, 0.94 ng/mL; range, 0.15–89.91 ng/mL) and suspected recurrent PCa. A total of 187 patients had undergone primary radical prostatec...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
Our objective was to investigate the lesion detection rate of 18F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)–targeted PET agent, in patients with biochemically relapsed prostate cancer after primary local therapy. Methods: This was a prospective institutional review board–approved study of 90 patients with documented biochemical recurrence (median prostate-specific antigen [PSA], 2.5 ng/mL; range, 0.21–35.5 ng/mL) and negative results on conventional imaging after primary local therapies, including radical prostatectomy (n = 38), radiation (n = 27), or a combination of the two (n = 25). Pa...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
eriaudeau In this paper, we present an evaluation of four encoder–decoder CNNs in the segmentation of the prostate gland in T2W magnetic resonance imaging (MRI) image. The four selected CNNs are FCN, SegNet, U-Net, and DeepLabV3+, which was originally proposed for the segmentation of road scene, biomedical, and natural images. Segmentation of prostate in T2W MRI images is an important step in the automatic diagnosis of prostate cancer to enable better lesion detection and staging of prostate cancer. Therefore, many research efforts have been conducted to improve the segmentation of the prostate gland in MRI i...
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
ConclusionsWe have successfully synthesized the radiotracer [18F]2 ‐amino‐4‐((2‐((3‐fluorobenzyl)oxy)benzyl)(2‐((3‐(fluoromethyl)benzyl)oxy)benzyl)amino)butanoic acid.In vitro experiments show a good affinity for both the human and rat ASCT ‐2. However, the tracer suffers from poorin vivo tumor uptake in the PC ‐3 model. Briefly, we present the first fluorine‐18 labelled derivative of compound V‐9302, a promising novel ASCT‐2 blocker used for inhibition of tumor growth.
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
Publication date: Available online 28 May 2020Source: Radiation Physics and ChemistryAuthor(s): Chen Ew-Jun, Tan Teik Hin, Chew Ming Tsuey
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
ConclusionsIntegrated [68Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [68Ga]PSMA-11 PET/MRI is superior compared with [68Ga]PSMA-11 PET/CT.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Carbon-ion radiotherapy (CIRT) for prostate cancer was initiated at Kanagawa Cancer Center in 2015. The present study analyzed the preliminary clinical outcomes of CIRT for prostate cancer.
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Conclusion: Our patient, diagnosed with recurrent prostate BCC after receiving a radical prostatectomy, responded to treatment with etoposide. Radical prostatectomy and radiotherapy should remain first-line therapy; however, etoposide may be an alternative second-line therapy when other options are not available. Consensus regarding treatment plans, and the molecular mechanisms behind prostate BBC, must be elucidated.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Hormones | Legislation | PET Scan | Prostate Cancer | Study | Sweden Health | Urology & Nephrology